Eosinophilic Esophagitis Treatment Market
Global Eosinophilic Esophagitis Treatment Market Size, Share & Trends Analysis Report By Product (Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, and Others), By Diagnosis (Upper Endoscopy, Esophagus Biopsy, and Blood Tests), and By Treatment (Dietary Therapy, Medication, and Dilation) Forecast, 2022-2028
The global eosinophilic esophagitis treatment market is growing at a CAGR of 6.4% during the forecast period. One of the major factors that are augmenting the growth of the eosinophilic esophagitis treatment market is increasing awareness programs for eosinophil-associated disorders. Moreover, the growing preference for personalized medicine and point-of-care testing along with the increasing development of a potential drug is also estimated to be the other important factor that is contributing significantly towards the growth of the market.
However, high-cost involvement and lack of awareness are some factors constraints that are hindering the growth of the global eosinophilic esophagitis treatment market across the globe. Moreover, the rising technological advancements and modernization in the healthcare sector in emerging regions are some of the key factors that are creating opportunities for the market. A new offering in the market is likely to drive the growth of the global eosinophilic esophagitis treatment market. For instance, in October 2021, AstraZeneca’s tezelpelumab had received the approval from FDA for the treatment of eosinophilic esophagitis.
Impact of COVID-19 Pandemic on Global Eosinophilic Esophagitis Treatment Market
The COVID-19 pandemic had impacted various industries in an adverse manner. Additionally, the global eosinophilic esophagitis treatment market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in these major economies has disrupted manufacturing and transportation across the globe. The eosinophilic esophagitis treatment was also declined due to the disruptions in the supply chain of essential medical supplies and medical devices.
Segmental Outlook
The market is segmented based on product, diagnosis, and treatment. By product, the market is segmented into budesonide oral suspension, fluticasone ODT, mepolizumab, reslizumab, benralizumab, and others. Further, based on the diagnosis segment, the market is segmented into upper endoscopy, esophagus biopsy, and blood tests. Based on the treatment segment, the market is divided into dietary therapy, medication, and dilation.
Global Eosinophilic Esophagitis Treatment Market Share Product, 2021 (%)
Budesonide Oral Suspension Expected to Hold Prominent Market Share in the Global Eosinophilic Esophagitis Treatment Market
Based on the product, the budesonide oral suspension segment holds a significant share in the iron-deficiency anemia market. Budesonide oral suspension is regarded as the novel topical corticosteroid, which is supporting in improving symptoms and endoscopic appearance. Additionally, it supports decreasing peak eosinophil counts in patients with eosinophilic esophagitis.
Regional Outlooks
The global eosinophilic esophagitis treatment market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in the global Eosinophilic Esophagitis Treatment Market. Some factors that are boosting the market growth in North America are technologically advanced products and the present increasing cases related to eosinophilic esophagitis. For instance, as per the information provided by American Partnership for Eosinophilic Disorders in 2020, Eosinophilic esophagitis pervasiveness is growing and impacting people of all ages, and a higher incidence is observed in males. Additionally, the existence of a large number of players providing effective offerings is some other main factor that is providing support to the growth of the market in the region.
Global Eosinophilic Esophagitis Treatment Market Growth, by Region 2022-2028
Asia-Pacific will have considerable growth in the Global Eosinophilic Esophagitis Treatment Market
The Asia-Pacific region is expected to witness significant growth opportunities for the market. Improving health care infrastructure along with increasing health awareness among people is acting as the prime factor impacting the market in the region. Additionally, technology advancement and industry players are having large scope in this region especially in South Korea, China, and India for increasing their activity in the market.
Market Players Outlook
The prominent players functioning in the global eosinophilic esophagitis treatment market include AstraZeneca, Bristol-Myers Squibb, Novartis AG, Regeneron Pharmaceuticals, Inc., and Teva Pharmaceuticals Industries Ltd. among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships, and collaborations, and many others to thrive in a competitive environment. For instance, in December 2021, Allakos, Inc., which is considered as a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases had introduced the data for ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study for lirentelimab in patients with biopsy-confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, which highlighted the fact that both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints.
In October 2021, Regeneron Pharmaceuticals, Inc. along with Sanofi had announced results from its second Phase 3 trial assessing the investigational for the usage of Dupixent (dupilumab) in patients 12 years and older suffering from eosinophilic esophagitis.
In March 2019, Adare Pharmaceuticals, Inc. had set forth the positive results from its Phase IIb study (FLUTE) for one of its rare disease investigational products, APT-1011 (AdvaTab Fluticasone) for Eosinophilic Esophagitis as it can lead to inflammation and ultimately strictures and narrowing of the esophagus, putting patients at risk of food impaction. Additionally, APT-1011 is a novel formulation that is developed with the support of Adare’s proprietary AdvaTab technology along with the fluticasone product in advanced clinical development for giving effective treatment for Eosinophilic Esophagitis.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global eosinophilic esophagitis treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Eosinophilic Esophagitis Treatment Market by Product
4.1.1. Budesonide Oral Suspension
4.1.2. Fluticasone ODT
4.1.3. Mepolizumab
4.1.4. Reslizumab
4.1.5. Benralizumab
4.1.6. Others
4.2. Global Eosinophilic Esophagitis Treatment Market by Diagnosis
4.2.1. Upper Endoscopy
4.2.2. Esophagus Biopsy
4.2.3. Blood Tests
4.3. Global Eosinophilic Esophagitis Treatment Market by Treatment
4.3.1. Dietary Therapy
4.3.2. Medication
4.3.3. Dilation
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Adare Pharmaceuticals, Inc.
6.2. Allakos, Inc.
6.3. Astrazeneca
6.4. Axcan Pharma, Inc.
6.5. Bristol-Myers Squibb
6.6. Celgene Corp.
6.7. Ception Therapeutics Inc.
6.8. Dr. Falk Pharma Gmbh
6.9. DBV Technologies
6.10. Hikma Pharmaceuticals Plc
6.11. Novartis AG
6.12. Perrigo Co. Plc
6.13. Regeneron Pharmaceuticals, Inc.
6.14. Sun Pharmaceutical Industries Ltd.
6.15. Teva Pharmaceuticals Industries Ltd.
1. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
2. GLOBAL BUDESONIDE ORAL SUSPENSION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL FLUTICASONE ODT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL MEPOLIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL RESLIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL BENRALIZUMAB MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHERS PRODUCT FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
9. GLOBAL UPPER ENDOSCOPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL ESOPHAGUS BIOPSY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL BLOOD TESTS FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
13. GLOBAL DIETARY THERAPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL MEDICATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL DILATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
19. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
20. NORTH AMERICAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
21. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
23. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
24. EUROPEAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
29. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2021-2028 ($ MILLION)
30. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)
31. REST OF WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET, 2022-2028 (%)
4. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY PRODUCT, 2021VS 2028 (%)
5. GLOBAL BUDESONIDE ORAL SUSPENSION MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL FLUTICASONE ODT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL MEPOLIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
8. GLOBAL RESLIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
9. GLOBAL BENRALIZUMAB MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
10. GLOBAL OTHERS PRODUCT FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
11. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY DIAGNOSIS, 2021VS 2028 (%)
12. GLOBAL UPPER ENDOSCOPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
13. GLOBAL ESOPHAGUS BIOPSY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
14. GLOBAL BLOOD TESTS FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
15. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY TREATMENT, 2021VS 2028 (%)
16. GLOBAL DIETARY THERAPY FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
17. GLOBAL MEDICATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
18. GLOBAL DILATION FOR EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
19. GLOBAL EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
20. US EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
21. CANADA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
22. UK EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
23. FRANCE EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
24. GERMANY EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
25. ITALY EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
26. SPAIN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF EUROPE EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
28. INDIA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
29. CHINA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
30. JAPAN EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
31. SOUTH KOREA EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF ASIA-PACIFIC EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF THE WORLD EOSINOPHILIC ESOPHAGITIS TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
